Praxis Precision Medicines, Inc. (PRAX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Praxis Precision Medicines’ loss per share topped expectations in the third fiscal quarter of 2026, based on preliminary results reported November 9, 2026, with EPS of -$3.23 topping the -$3.54 estimate by $0.31. The clinical-stage CNS-focused biotech posted GAAP net income of about -$94.2 million, down 27.5% from about -$73.9 million a year ago, alongside operating income of roughly -$106.9 million. Cash burn remained significant, with negative operating cash flow of around -$81.7 million during the quarter as the company continued funding development across its CNS pipeline, including programs such as PRAX-114, PRAX-944, and PRAX-562. For the next period, consensus calls for EPS of -$4.09 on revenue of $376,929.00.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. develops therapies for central nervous system disorders tied to imbalances in neuronal activity as a clinical-stage biopharmaceutical firm and clinical-stage Biotechnology company listed on NASDAQ as PRAX. Its pipeline spans small molecules and antisense medicines aimed at epilepsy, movement disorders, pain-related conditions, and depressive disorders, placing it in the drug-development end of the healthcare sector.
Today's Snapshot
PRAX closed slightly higher at 305.19, while its sector was weaker. Goldman Sachs, an investment bank, raised its share-price target for Praxis Precision Medicines to $592 while keeping a Buy rating.
Trading Volume
Below 10d avg (592.1K)
415.3K
vs S&P 500 Today
Moderate Outperformance
+0.30%
Updated: November 18, 2026 at 21:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$297.10 - $309.22Buy
- RSI (14)53.12Neutral
- Stochastic %K (14, 3, 3)50.70Neutral
- MACD Level (12, 26)10.19Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.